Novo Nordisk sees faster profit growth on demand for diabetes drug Ozempic
By Ludwig Burger (Reuters) – Danish drugmaker Novo Nordisk raised its full-year earnings outlook on strong sales of diabetes treatment Ozempic, also reporting a better-than-expected profit.